Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-01-05 5:40 pm Purchase | 2025-12-23 | 13G | Korro Bio, Inc. KRRO | Lynx1 Capital Management LP | 733,633 7.800% | 733,633 (New Position) | Filing History |
| 2025-12-29 4:33 pm Unchanged | 2025-12-26 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-12-02 08:20 am Unchanged | 2025-12-02 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-11-28 09:09 am Unchanged | 2025-11-28 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-11-18 08:25 am Unchanged | 2025-11-18 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 16.300% | 0 (Unchanged) | Filing History |
| 2025-11-14 2:02 pm Purchase | 2025-09-30 | 13G | Precision BioSciences, Inc. DTIL | Lynx1 Capital Management LP | 1,042,596 8.800% | 276,545 (+36.10%) | Filing History |
| 2025-11-14 2:01 pm Purchase | 2025-09-30 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 623,704 19.600% | 160,856 (+34.75%) | Filing History |
| 2025-11-14 2:01 pm Purchase | 2025-09-30 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 8,601,189 13.900% | 2,248,120 (+35.39%) | Filing History |
| 2025-11-14 2:00 pm Sale | 2025-09-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Lynx1 Capital Management LP | 5,766,090 9.800% | -2,782,994 (-32.55%) | Filing History |
| 2025-11-10 2:33 pm Unchanged | 2025-11-09 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 26.500% | 0 (Unchanged) | Filing History |
| 2025-10-23 7:52 pm Purchase | 2025-10-21 | 13D | Neuphoria Therapeutics Inc. NEUP | Lynx1 Capital Management LP | 875,328 37.100% | 875,328 (New Position) | Filing History |
| 2025-10-10 6:53 pm Purchase | 2025-10-08 | 13G | Cullinan Therapeutics, Inc. CGEM | Lynx1 Capital Management LP | 8,549,084 14.500% | 4,148,242 (+94.26%) | Filing History |
| 2025-08-14 07:06 am Purchase | 2025-06-30 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 7,857,347 15.000% | 2,500,000 (+46.66%) | Filing History |
| 2025-08-14 06:58 am Purchase | 2025-06-30 | 13G | Cullinan Therapeutics, Inc. CGEM | Lynx1 Capital Management LP | 4,400,842 7.500% | 4,400,842 (New Position) | Filing History |
| 2025-02-14 09:02 am Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Lynx1 Capital Management LP | 10,874,723 5.200% | 10,874,723 (New Position) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | Passage Bio, Inc. PASG | Lynx1 Capital Management LP | 462,848 15.000% | 41,500 (+9.85%) | Filing History |
| 2025-02-14 09:01 am Purchase | 2024-12-31 | 13G | Precision BioSciences, Inc. DTIL | Lynx1 Capital Management LP | 766,051 9.990% | 766,051 (New Position) | Filing History |
| 2025-02-14 09:00 am Purchase | 2024-12-31 | 13G | TScan Therapeutics, Inc. TCRX | Lynx1 Capital Management LP | 5,357,347 10.900% | 132,747 (+2.54%) | Filing History |
| 2025-02-10 5:29 pm Purchase | 2025-02-06 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 6,353,069 10.200% | 1,494,075 (+30.75%) | Filing History |
| 2025-02-10 5:22 pm Purchase | 2024-12-31 | 13G | GH Research PLC GHRS | Lynx1 Capital Management LP | 4,858,994 9.300% | 663,100 (+15.80%) | Filing History |